NeoGenomics, Inc. (NEO)
| Market Cap | 6.36B |
| Revenue (ttm) | 425.32M |
| Net Income (ttm) | -4.95M |
| Shares Out | 110.46M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 169.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $55.29 |
| Previous Close | $56.19 |
| Change ($) | -0.90 |
| Change (%) | -1.60% |
| Day's Open | 56.71 |
| Day's Range | 54.75 - 57.00 |
| Day's Volume | 1,068,218 |
| 52-Week Range | 20.50 - 57.00 |
FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract rese...
FORT MYERS, FL / ACCESSWIRE / January 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract rese...
FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, tod...
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Costco and Twitter
NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at c...
NeoGenomics, Inc.'s (NEO) CEO Doug VanOort on Q3 2020 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2020 Results - Earnings Call Transcript
Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.
NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These pioneers will be winners however the pandemic plays out.
NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. The post NeoGenomics Shows Market Leadership With Jump To 81 RS Rating appeare...
A Relative Strength Rating upgrade for NeoGenomics shows improving technical performance. Will it continue?
Near-term headwinds won’t damage the long-term prospects of these two companies.
The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.
Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.
Neogenomics Inc. (NEO) CEO Doug VanOort on Q1 2020 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?
Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.
Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.
Advances in precision medicine continue to propel the leader in oncology testing services.
The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.
NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q4 2019 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These two stocks are supported by solid long-term opportunities, but they couldn't be more different.
Which biotech was a 37-bagger?
These genetic testing stocks took divergent paths in the final months of 2019, but they're solid options for investors with a long-term mindset.
Helping people stricken with illness can be richly rewarding in more ways than one.
The cancer-focused genetic testing service provider upgraded its offerings to provide higher-quality data from the same biological samples. That should keep growth humming along.
NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q3 2019 Results - Earnings Call Transcript
An excellent third-quarter performance for the genetic testing company has investors cheering.
NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
These stocks have track records of success and plenty of growth ahead.
Most stocks in the industry cooled off from all-time highs. Will they keep sliding?
These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.
It was a great month to be a genetic testing company.
Investor's Business Daily: NeoGenomics, Inc.
Trump tariffs slam stocks: NeoGenomics breaks out.
NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2019 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The genetic testing leader continues to set new quarterly revenue records.
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NeoGenomics' (NEO) CEO Doug VanOort on Q1 2019 Results - Earnings Call Transcript
About NEO
NeoGenomics operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationshi... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 2, 1999 |
| CEO Douglas M. VanOort | Employees 1,700 |
| Stock Exchange NASDAQ | Ticker Symbol NEO |
Financial Performance
In 2019, NeoGenomics's revenue was $408.83 million, an increase of 47.73% compared to the previous year's $276.74 million. Earnings were $8.01 million, an increase of 203.26%.
Analyst Forecasts
According to 11 analysts, the average rating for NeoGenomics stock is "Strong Buy." The 12-month stock price forecast is 52.50, which is a decrease of -5.05% from the latest price.